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Article
Abstract
Objectives  The aim of this Phase III, 
multicentre, open-label, randomised study 
was to compare the efﬁ  cacy and safety of 
ethinylestradiol (EE)/drospirenone (DRSP) in a 
new ﬂ  exible extended regimen that allowed 
the management of intracyclic (breakthrough) 
bleeding (MIB) with that of EE/DRSP in a 
conventional 28-day regimen in women with 
moderate-to-severe primary dysmenorrhoea.
Methods  Women (aged 18–40 years) with 
moderate-to-severe primary dysmenorrhoea-
related pain received a ﬂ  exible extended regimen 
with MIB (ﬂ  exibleMIB; minimum 24, maximum 
120 days of continuous tablet intake for a 
ﬂ  exible number of cycles to reach a treatment 
duration of at least 140 days with 4-day breaks 
between cycles) or a conventional 28-day 
regimen (24 active and four placebo tablets for 
ﬁ  ve cycles) of EE/DRSP. The primary outcome was 
the number of days with dysmenorrhoeic pain 
over 140 days. Secondary outcomes included 
other dysmenorrhoea-related pain outcomes, 
bleeding proﬁ  le, satisfaction and safety.
Results  Overall, 223 patients received study 
medication. There were signiﬁ  cantly fewer days 
with dysmenorrhoeic pain with the ﬂ  exibleMIB 
regimen than the conventional regimen 
(difference −4.2 days, 95% CI −6.5 to −2.0; 
p=0.0003), as well as considerably fewer days 
with at least moderate dysmenorrhoeic pain 
(difference −2.5 days, 95% CI −3.7 to −1.3), 
dysmenorrhoeic pain that interfered with 
daily activities (difference −2.2 days, 95% 
CI −4.2 to −0.1) and pelvic pain (difference 
−3.4 days, 95% CI −5.9 to −0.9). Adverse 
events were similar with both regimens.
Conclusions  Compared with the conventional 
regimen, the ﬂ  exible extended regimen 
of EE/DRSP with MIB was associated with 
a signiﬁ  cantly greater reduction in days 
with dysmenorrhoeic pain in women with 
moderate-to-severe primary dysmenorrhoea. 
The ﬂ  exibleMIB regimen was also associated 
with greater improvements in dysmenorrhea 
according to the Clinical Global Impression 
rating scale and was generally well tolerated.
Introduction
Primary dysmenorrhoea is characterised by 
cramping pain in the lower abdomen and/
or pelvis just before or during menstrua-
tion, without any identifiable pelvic dis-
ease. Dysmenorrhoea usually presents with 
or shortly after menarche, is most preva-
lent in adolescent women and becomes less 
prevalent with increasing age.1–3 Estimates 
of the prevalence of dysmenorrhoea vary 
depending on the method of assessment, 
but range from around 20–90% in adoles-
cents.4 Dysmenorrhoea can have a signifi-
cant impact on quality of life and school/
work absenteeism.3 Despite the high prev-
alence of dysmenorrhoea and the consid-
erable effect that it may have on daily life, 
few women consult their physicians about 
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Key message points
▶   Ethinylestradiol 20 μg/drospirenone 3 mg in a ﬂ  exible 
extended regimen versus a conventional regimen 
resulted in signiﬁ  cantly fewer days with dysmenorrhoeic 
pain in women with primary dysmenorrhoea.
▶   In the investigators’ assessment, more women in the 
ﬂ  exible extended regimen group were ‘very much’ or 
‘much’ improved, compared with the conventional 
regimen group.
▶   Women were generally satisﬁ  ed with their regimen, 
and satisfaction scores were similar between the 
two groups.
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their condition;2 additionally, low physician awareness 
means that dysmenorrhoea is often inadequately rec-
ognised and treated.1
A range of treatments exist for dysmenorrhoea, 
and the majority of women self-medicate with over-
the-counter (OTC) non-steroidal anti-inflammatory 
drugs (NSAIDs), resulting in reduced pain.2 3 However, 
NSAIDs are associated with gastrointestinal adverse 
events (AEs)/complications that can cause high levels 
of morbidity and cost.5
Although the results from a systematic review did 
not find a conclusive effect for the use of combined 
oral contraceptives (COCs) with a conventional 28-day 
regimen in women with dysmenorrhoea,6 it is thought 
they may have a positive effect in this setting. There is 
evidence that fixed extended COC regimens may be 
effective in such women.7 It is postulated that extend-
ing active hormonal intake of COCs beyond 28 days 
might have use in reducing the frequency and intensity 
of menses. This may consequently lead to a reduction 
in the symptoms of dysmenorrhoea and the factors 
that influence dysmenorrhoea (such as pituitary gona-
dotropin production and ovarian activity).
This study was designed to compare the efficacy and 
safety of a flexible extended regimen of  ethinylestradiol 
(EE)/drospirenone (DRSP) that allows the management 
Figure 1  Disposition of women through the study. FAS, full analysis set. MIB, management of intracyclic (breakthrough) bleeding.
Table 1  Baseline demographics and clinical characteristics (full analysis set)
Demographic/characteristic 
FlexibleMIB (n=115) Conventional (n=108)
[mean (SD)] [mean (SD)]
Age (years) 25.6   (5.1) 25.3   (5.0)
Height (cm) 167.6   (6.0) 168.2   (6.5)
Weight (kg) 63.1   (9.5) 63.8   (9.1)
BMI (kg/m2) 22.4   (2.9) 22.5   (3.0)
Length of pretreatment screening period (days) 79.6 (21.3) 81.3 (25.5)
Number of days with dysmenorrhoeic pain before treatment (>140 days)* 21.0   (7.3) 22.0   (8.4)
Number of days with at least moderate dysmenorrhoeic pain before treatment (>140 days)* 12.8   (5.7) 13.8   (7.4)
*Data were normalised to a 140-day period to allow comparisons with the 140-day treatment period. Pretreatment periods had a minimum length of 
46 days. Data was cut after the ﬁ  rst 140 days of the pretreatment period.
BMI, body mass index; MIB, management of (breakthrough) intracyclic bleeding; SD, standard deviation.
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of intracyclic (breakthrough) bleeding (flexibleMIB) with 
a conventional 28-day regimen of EE/DRSP in women 
with moderate-to-severe primary dysmenorrhoea.
Methods
Study design
This was a Phase III, multicentre, open-label, ran-
domised, active-controlled, parallel-group study con-
ducted in 26 centres in Germany and three centres in 
the UK between December 2007 and December 2009.
The study (ClinicalTrials.gov identifier, NCT00569244) 
was conducted in accordance with the International 
Conference on Harmonisation–Good Clinical Practice 
guidelines and Declaration of Helsinki. All participants 
had to have voluntarily signed an informed consent form 
before entering the study.
Study population
Women aged 18–40 years (≤30 years for smokers 
with a daily cigarette consumption of ≤10) with mod-
erate-to-severe primary dysmenorrhoea (moderate-
to-severe menstruation-related pelvic pain in at least 
four of six of the preceding cycles) were enrolled. 
Moderate dysmenorrhoea was defined as requiring 
OTC analgesics during menstruation with significant 
pain relief upon intake, as well as the presence of 
symptoms that interfere with usual activities. Severe 
dysmenorrhoea was defined as requiring analgesics 
during menstruation, with inconsistent relief from 
OTC analgesics, prescription analgesics required in at 
least some cycles, as well as discomfort that resulted 
in an inability to work or to carry out usual activities. 
Additionally, to meet the inclusion criteria, patients 
were required to have a self-rated sum pain total 
score of at least eight on the Andersch and Milsom 
dysmenorrhoea grading scale8 over the two baseline 
menstrual cycles.
At the screening phase, eligible women were grouped 
as COC switchers (who were required to have a wash-
out phase comprising three menstrual cycles, the sec-
ond and third of which constituted baseline cycles one 
and two) or COC starters (who did not require a wash-
out phase and simply had two baseline cycles).
Study regimens
Eligible women were randomly allocated to one of two 
regimens of EE/DRSP: a flexibleMIB and a conventional 
28-day regimen. For the flexibleMIB group, women 
took EE 20 µg/DRSP 3 mg at around the same time 
each day, continuously for at least 24 days (mandatory 
phase). After 24 days, EE/DRSP tablets could be con-
tinued for up to a maximum of 120 consecutive days 
(flexible intake phase). During the flexible intake phase 
(Days 25–120) women were, however, instructed to 
finish the intake cycle by observing a 4-day tablet-free 
interval if they experienced three consecutive days of 
bleeding or spotting. The 4-day tablet-free interval had 
to be taken no later than after a maximum 120 days of 
continuous tablet intake. After each 4-day tablet-free 
interval, women started a new cycle with a minimum 
of 24 days and a maximum of 120 days. Treatment was 
intended to last at least 140 days and, therefore, a flex-
ible number of cycles were required to reach this dura-
tion, with the 140 days including at least one 4-day 
tablet-free interval.
For the conventional group, women took EE 20 µg/
DRSP 3 mg for five 28-day cycles (total 140 days); 
each cycle consisted of 24 days of active hormonal 
intake followed by a 4-day hormone-free interval (dur-
ing which women received hormone-free tablets).
Patients were permitted to take ibuprofen as rescue 
medication (which was documented).
Study variables
The primary efficacy variable was the number of 
days with dysmenorrhoeic pain over 140 days. 
Dysmenorrhoeic pain was defined as any spasmodic 
pelvic, lower abdominal pain with possible radiation 
Figure 3  Mean number of days with various pain outcomes 
and use of rescue medication over 140 days (full analysis set). 
MIB, management of intracyclic (breakthrough) bleeding.
Figure 2  Mean number of days with dysmenorrhoeic pain 
over 140 days (full analysis set). CI, conﬁ  dence interval; MIB, 
management of intracyclic (breakthrough) bleeding.
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towards the back or thighs recorded in a daily diary in 
correspondence with a withdrawal and/or menstrual 
bleeding episode. Pain severity was self-assessed on 
a daily basis using a verbal rating scale with the fol-
lowing four categories: 0, no pain; 1, mild dysmenor-
rhoeic pain with no need for an analgesic; 2, moderate 
dysmenorrhoeic pain with need for an analgesic; and 
3, severe dysmenorrhoeic pain with the need for an 
analgesic.
Secondary efficacy variables included: days with 
at least moderate dysmenorrhoeic pain; days with 
dysmenorrhoeic pain associated with withdrawal or 
unscheduled bleeding; days with pelvic pain; days 
with dysmenorrhoeic pain that interfered with daily 
activities; bleeding profile (including the number of 
days and episodes of bleeding/spotting by 90-day ref-
erence periods, bleeding intensity (none, spotting, 
light, normal or heavy) and the proportion of sub-
jects with withdrawal and intracyclic bleeding dur-
ing individual cycles); investigator-assessed global 
improvement in dysmenorrhoea (seven-point scale 
ranging from 1=very much improved to 7=very 
much worse); and user satisfaction (seven-point scale 
ranging from 1=very much satisfied, to 7=very much 
dissatisfied).
Safety evaluations included AEs, metabolic param-
eters, carbohydrate metabolism, vital signs, clini-
cal laboratory tests, and physical and gynaecological 
examinations.
Statistical analysis
The study sample size was determined on the assump-
tion that for the primary efficacy variable there would 
be a mean difference between the flexibleMIB and con-
ventional groups of 5 days, with a standard deviation 
(SD) of 10 days. Based on a standardised effect size 
of 0.5, a dropout rate of 20%, α of 0.05 (two-sided) 
and 90% power, a sample size of 108 women per 
regimen was required to have 86 evaluable women per 
group. At screening, eligible subjects were sequentially 
assigned a unique three-digit patient identification 
number. Subjects were then randomised 1:1 using a 
computer-generated randomisation list using randomi-
sation blocks of four. These blocks were assigned to 
study centres. Within each centre the allocation of a 
randomisation number was linked in a chronologically 
ascending manner to the sequence of arrival of the 
patients at the study centre.
All data were evaluated according to the type of 
data, that is, descriptive statistics (including at least 
arithmetic mean, SD, minimum, median and maxi-
mum) for continuous variables and frequency tables 
for categorical data. All women who took at least one 
unit of study medication and for whom at least one 
observation after dosing was available were included 
in the full analysis set (FAS). A two-sample t-test was 
used to analyse the primary efficacy variable. For the 
difference between the two treatment groups, two-
sided 95% CI were calculated for the primary effi-
cacy variable and for the secondary efficacy variables 
related to dysmenorrhoeic pain. All other variables 
were analysed descriptively.
Results
A total of 223 patients who received study medication 
were included in the FAS (flexibleMIB regimen, n=115; 
conventional regimen, n=108) and 210 patients (110 
and 100, respectively) completed the study as planned 
(Figure 1). Baseline characteristics were similar for the 
two regimens and are outlined in Table 1.
Overall, compliance was good for both regimens: the 
mean (SD) number of tablets taken in the   flexibleMIB 
group was 151.8 (31.8) with a median of 146.0; corre-
sponding tablet numbers in the conventional regimen 
group were 135.6 (26.0) and 140.0, respectively.
Table 2  Bleeding/spotting outcomes by 90-day reference period (full analysis set)
90-day 
phase
FlexibleMIB Conventional
n Mean (SD) Median Range Q1, Q3 n Mean (SD) Median Range Q1, Q3
Number of days with bleeding/
spotting
1 111 19.9 (13.0) 17 1–66 10.0, 30.0 101 25.3 (9.1) 23 4–49 18.0, 30.0
2 90 12.9   (8.3) 12 0–38 7.0, 16.0 47 15.7 (5.9) 15 0–37 13.0, 18.0
Number of bleeding/spotting 
episodes
1 93 2.4   (1.7) 2 0–10 1.0, 3.0 101 3.5 (1.0) 3 1–8 3.0, 4.0
2 90 2.7   (1.7) 3 0–10 2.0, 3.0 47 3.2 (0.8) 3 0–5 3.0, 4.0
Length of bleeding/spotting 
episodes
1 92 7.8   (9.0) 6 1–79 3.6, 9.0 101 5.2 (1.8) 5 2–12 4.0, 6.0
2 85 5.1   (2.5) 5 1–15 3.5, 6.0 46 5.1 (1.5) 5 2–9 4.0, 6.3
Maximum length of bleeding/
spotting episodes
1 92 10.2   (9.7) 9 1–79 5.5, 11.0 101 7.5 (3.7) 6 3–20 5.0, 8.0
2 85 6.9   (3.9) 6 1–23 5.0, 8.0 46 6.0 (1.7) 6 2–11 5.0, 7.0
Range of length of bleeding/
spotting episodes
1 92 4.5   (5.4) 3 0–31 0, 8.0 101 3.9 (3.9) 3 1–19 1.0, 5.0
2 85 3.3   (4.0) 2 0–22 0, 4.0 46 2.0 (1.9) 1 0–7 1.0, 3.0
NB. The ﬁ  rst period includes the bleeding at treatment start. At least 60 days with data were required to be included in the evaluation of a 90-day period. In 
the conventional group regular treatment ended before Day 150, which led to the exclusion of many subjects in period 2.
MIB, management of intracyclic (breakthrough) bleeding; Q, quartile; SD, standard deviation.
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Primary efﬁ  cacy variable
Dysmenorrhoeic pain
Over 140 days, the flexibleMIB regimen was associated 
with significantly fewer days with dysmenorrhoeic pain 
compared with the conventional regimen [mean (SD) 
10.6 (6.7) vs 14.9 (8.9) days, respectively] (Figure 2). 
The difference between the two regimens was −4.2 
days (95% CI −6.5 to −2.0, p=0.0003).
Secondary efﬁ  cacy variable
Other dysmenorrhoeic pain outcomes
Consistent with the results of the primary efficacy vari-
able, over 140 days, the flexibleMIB regimen also pro-
vided considerably fewer days with at least moderate 
dysmenorrhoeic pain (treatment difference −2.5 days, 
95% CI −3.7 to −1.3), days with dysmenorrhoeic pain 
associated with withdrawal bleeding (−4.1 days, 95% 
CI −5.8 to −2.4), days in which dysmenorrhoeic pain 
interfered with daily activities (−2.2 days, 95% CI 
−4.2 to −0.1), and days with pelvic pain (independent 
of vaginal bleeding; −3.4 days, 95% CI −5.9 to −0.9) 
than the conventional regimen (Figure 3). The mean 
number of days with dysmenorrhoeic pain associated 
with unscheduled bleeding (−0.1 days, 95% CI −1.3 
to 1.0) and the use of rescue medication (−1.0 days, 
95% CI −2.5 to 0.5) was similar for both regimens 
(Figure 3).
Other efﬁ  cacy variables
Baseline comparison
Patients in this study had to undergo a screening period 
in which the number of days with pain from dysmen-
orrhea was recorded. Because patients were not receiv-
ing COCs for up to three menstrual cycles during this 
period, it was possible to compare the number of days 
with pain during screening with the number of days 
with pain during treatment. For this purpose, pre-
  treatment days with dysmenorrhoeic pain were pro-
jected to a 140-day period. The mean (SD) number 
of days with dysmenorrhoeic pain pre-  treatment in 
patients who received the flexibleMIB regimen and the 
conventional regimen was 21.0 (7.3) and 22.0 (8.4), 
respectively (Table 1). When looking at the results of 
the primary efficacy variable (see above), the overall 
benefit of treatment in terms of a reduction in the 
total number of days with dysmenorrhoeic pain was 
approximately one-third for patients who received the 
conventional regimen and approximately one-half for 
patients who received the flexibleMIB regimen.
Number of days with dysmenorrhoeic pain in relation to cycle length
In an exploratory post hoc analysis, the number of 
days of pain in patients who received the flexibleMIB 
regimen were analysed according to the length of the 
flexible intake cycle. In patients with cycle lengths 
of less than 42 days, the mean (SD) number of days 
with dysmenorrhoeic pain was 13.0 (8.8); this was 
approximately two fewer days with dysmenorrhoeic 
pain, compared with patients who received the con-
ventional regimen. In contrast, in patients with a cycle 
length of 42 days or more, the mean (SD) number of 
days with dysmenorrhoeic pain was 8.6 (6.3); this rep-
resented more than seven fewer days with dysmenor-
rhoeic pain, compared with patients who received the 
conventional regimen. This suggests that the advan-
tage of the flexibleMIB regimen is a result of an exten-
sion of the menstrual cycle.
Bleeding proﬁ  le
During the two 90-day reference periods in which the 
bleeding profile was analysed there were a lower mean 
and median number of bleeding/spotting days observed 
in the flexibleMIB group compared with the conven-
tional group (Table 2). Likewise, the mean number of 
bleeding/spotting episodes was lower in the flexibleMIB 
group than in the conventional group. However, the 
mean length, maximum length and range of length 
of bleeding/spotting episodes were all slightly higher 
in the flexibleMIB group than the conventional group 
(Table 2).
During the individual cycles, the proportion of 
women with withdrawal bleeding was similar in both 
Table 3  Most frequent adverse events occurring in >2% of women in either regimen 
(full analysis set)
Adverse event
FlexibleMIB Conventional
Events (n) Subjects [n (%)] Events (n) Subjects [n (%)]
Headache 7 6 (5.2) 10 6 (5.6)
Nasopharyngitis 8 8 (7.0) 4 4 (3.7)
Breast pain 3 3 (2.6) 4 4 (3.7)
Vaginal infection 5 5 (4.3) 2 2 (1.9)
Diarrhoea 4 4 (3.5) 2 2 (1.9)
Vomiting 2 2 (1.7) 5 4 (3.7)
Cystitis 2 2 (1.7) 5 3 (2.8)
Acne 3 3 (2.6) 1 1 (0.9)
MIB, management of intracyclic (breakthrough) bleeding.
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regimens [range of the percentages over time for all 
cycles: 86–97% (n=9–110) in the flexibleMIB group 
and 87–98% (n=79–99) in the conventional group]. 
The mean length of withdrawal bleeding episodes 
tended to be longer with the flexibleMIB regimen 
and the onset of the withdrawal bleeding episode in 
the flexibleMIB group was 3 days early in relation to 
the hormone-free interval. A similar proportion of 
women had withdrawal bleeding of light or moderate 
intensity in the two groups, but there was a lower fre-
quency of heavy intensity withdrawal bleeding in the 
  flexibleMIB group versus the conventional group during 
the individual cycles [range 15.9–22.7% (n=2–24) in 
the flexibleMIB group and 24.5–29.8% (n=22–28) in 
the conventional regimen group].
The occurrence of intracyclic bleeding, the number 
of intracyclic bleeding days and episodes was notice-
ably higher in the flexibleMIB group in the first cycle, 
but decreased in the subsequent cycles. Despite these 
differences, the maximum length and the maximum 
intensity of intracyclic bleeding episodes were similar 
in the two groups.
Clinical Global Impression scale
Based on the investigator’s assessment of the degree of 
improvement of primary dysmenorrhoea, 40 (34.8%) 
and 60 (52.2%) women receiving the flexibleMIB regi-
men were considered to be ‘very much’ or ‘much’ 
improved, respectively. The corresponding values in 
the conventional regimen group were 43 (39.8%) and 
40 (37.0%). The number of women considered to be 
‘minimally improved’ or ‘unchanged’ was 12 (10.4%) 
and 20 (18.5%) in the two groups, respectively, while 
the number of women with dysmenorrhoea that wors-
ened (‘minimally’, ‘much’ and ‘very much’ worse) was 
3 (2.6%) and 5 (4.7%), respectively.
User satisfaction
Women were generally satisfied with their regimen. 
Overall, 25 (21.7%) and 63 (54.8%) women receiving 
the flexibleMIB regimen were ‘very much satisfied’ or 
‘much satisfied’ with it. The corresponding values in 
the conventional regimen group were 26 (24.1%) and 
54 (50.0%). The number and proportion of women 
who were ‘minimally satisfied’ or ‘neither satisfied 
or dissatisfied’ was similar [20 (17.4%) in flexibleMIB 
group and 16 (14.8%) in the conventional regimen 
group]. In the flexibleMIB group, 7 (6.1%) women were 
‘minimally’, ‘much’ or ‘very much’ dissatisfied com-
pared with 12 (11.1%) women in the conventional 
regimen group.
Safety
In total, 82 (36.8%) women reported experienc-
ing at least one AE, with a similar incidence between 
the   flexibleMIB (n=44; 38.3%) and the conventional 
(n=38; 35.2%) regimens. AEs that occurred in >2% 
of the total sample are detailed in Table 3. No deaths 
or serious AEs were reported in the study.
The levels of various metabolic parameters (including 
total cholesterol, triglycerides, low-density lipoprotein 
cholesterol and high-density lipoprotein cholesterol) 
and potassium remained normal and generally stable 
in both treatment groups. Similarly, levels of glyco-
sylated haemoglobin remained normal and generally 
stable in both treatment groups over the course of the 
study. Neither the flexibleMIB regimen nor the conven-
tional regimen adversely affected blood pressure, with 
mean values within normal limits. Mean body weight 
remained stable in both treatment groups. There were 
also no clinically meaningful changes in haematology 
and serum chemistry profiles with either regimen. No 
abnormal cervical smear test findings were observed at 
the final examination in any of the subjects. The results 
of the gynaecological examination revealed findings 
that were similar to those that would be expected in 
similar populations to the one recruited.
Discussion
In this 140-day study in women with moderate-to-
severe primary dysmenorrhoea, a flexible extended 
regimen of EE/DRSP with management of intracyclic 
(breakthrough) bleeding was found to reduce dysmen-
orrhoeic symptoms and was associated with better 
outcomes than the conventional 28-day regimen of 
EE/DRSP . Compared with a conventional regimen of 
24 days of active treatment followed by a 4-day tablet-
free interval, the flexibleMIB regimen was associated 
with significantly fewer days with dysmenorrhoeic 
pain over 140 days, as well as considerably fewer days 
with at least moderate dysmenorrhoeic pain, dysmen-
orrhoeic pain associated with withdrawal bleeding, 
days in which dysmenorrhoeic pain interfered with 
daily activities, and days with pelvic pain. This effect 
may have been even more pronounced if the   flexibleMIB 
regimen had been compared with a conventional 
28-day regimen COC that uses a 7-day hormone-free 
interval and 21 days of active treatment. Additionally, 
investigator-assessed global improvement and user sat-
isfaction scores were more favourable in the   flexibleMIB 
group compared with the conventional group. The 
small difference between the groups in favour of the 
flexibleMIB regimen may be explained by its bleeding 
pattern with fewer menstrual periods compared with 
the well-known standard application of COCs that 
mimic a normal menstrual cycle. Furthermore, the 
flexible extended regimen may lead to better patient 
compliance.
In addition to reducing the frequency of withdrawal 
bleeding episodes by extending the menstrual cycle, 
the benefit of the flexibleMIB regimen was that it pro-
vided a method to manage any intracyclic (break-
through) bleeding that occurred during the flexible 
intake phase (Days 25–120). By observing a 4-day tab-
let-free interval after experiencing three consecutive 
days of bleeding/spotting, breakthrough bleeding was 
turned into withdrawal bleeding. This facilitated better 
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management of intracyclic (breakthrough) bleeding, 
enabling women to experience fewer overall days of 
bleeding over 140 days and fewer bleeding episodes, 
compared with the conventional regimen.
The MIB strategy meant that the bleeding profile was 
somewhat different between the flexibleMIB regimen 
and the conventional regimen; the mean length, maxi-
mum length and range of length of bleeding/  spotting 
episodes and the mean length of withdrawal bleed-
ing episodes were all slightly higher in the flexibleMIB 
group than in the conventional group. This probably 
relates to the fact that, by definition, the withdrawal 
bleeding episode under treatment with the flexibleMIB 
regimen often included the 3-day ‘wait and see’ period 
of bleeding/spotting that was instructed before women 
managed their intracyclic (breakthrough) bleeding by 
taking a 4-day tablet-free interval. The onset of the 
withdrawal bleeding episode occurred 3 days earlier in 
relation to the hormone-free interval in the   flexibleMIB 
group compared with the conventional regimen. 
Again, this was likely a result of the 3-day ‘wait-and-
see’ period.
The occurrence of intracyclic bleeding, the number 
of intracyclic bleeding days and episodes and the max-
imum length of intracyclic bleeding episodes varied 
markedly between the two groups. Such differences 
can be explained, at least in part, by between-  treatment 
differences in the way in which data were analysed 
and differences in the two regimens themselves (as 
described above). In addition, the flexibleMIB regi-
men was designed to achieve prolonged bleeding-free 
intervals. While bleeding/spotting episodes of three 
consecutive days were to be managed by introducing 
a 4-day tablet-free interval (thus converting them into 
withdrawal bleeding episodes), episodes of bleeding/
spotting of less than 3 days were to be ignored. Not 
managing shorter bleeding/spotting episodes was con-
sidered a suitable strategy to avoid too frequent with-
drawal bleeding episodes; however, this ultimately 
increased the incidence of intracyclic bleeding in 
women who received the flexibleMIB regimen (data not 
shown).
There have been relatively few randomised studies 
that have specifically assessed the effect of continuous 
use or fixed extended regimens of COCs on dysmen-
orrhoea. Several studies have, however, assessed the 
effect of such regimens on menstrual-related symp-
toms in general, including dysmenorrhoea. In a study 
among women with menstrual-related symptoms 
(n=50), extending the number of consecutive days of 
active pills (up to a maximum of 12 weeks) was shown 
to reduce dysmenorrhoea, menorrhagia and premen-
strual symptoms.9 Two studies have shown that the 
COC EE 30 µg/DRSP 3 mg, when used continuously 
for either 84 or 168 days, improved menstrual-related 
symptoms, including dysmenorrhoea.10 11 In a study of 
32 women, continuous use of EE 20 µg/  levonorgestrel 
(LNG) 100 µg for 168 days was associated with 
significantly fewer bleeding days that required sani-
tary protection, significantly fewer days with bloating 
and significantly fewer days with menstrual pain (all 
p<0.05) compared with a conventional 28-day regi-
men of EE 20 µg/LNG 100 µg.12 A COC containing 
EE 30 µg/chlormadinone acetate 2 mg in an extended 
regimen has also been shown to be effective in women 
with dysmenorrhoea. In a pooled analysis of three 
large-scale observational studies assessing the benefits 
and risks of this COC in an extended regimen (mean 
treatment duration 5.8 months), a reduction in dys-
menorrhoea symptoms was observed, as measured 
by a reduction in analgesic use, absence from school/
university/work and restrictions in leisure and sporting 
activities.13 Overall, the results from the current study 
and those previously published support the extended 
use of COCs to reduce menstrual-related symptoms 
such as dysmenorrhoea.
In this study, both regimens were generally well tol-
erated and the overall incidence of AEs was similar 
between the two groups.
Conclusions
Compared with a conventional regimen of EE/
DRSP , a flexible extended regimen of EE/DRSP with 
management of intracyclic (breakthrough) bleeding 
was associated with better relief of dysmenorrhoeic 
complaints, including significantly fewer days with 
dysmenorrhoeic pain, in women with moderate-
to-severe primary dysmenorrhoea. The flexible 
extended regimen has the advantage of being able 
to delay menstruation for up to 124 days. The flex-
ible phase of the intake cycle allows women to react 
to the occurrence of breakthrough bleeding/spot-
ting by initiating a 4-day break that concludes the 
cycle. The strategy of managing breakthrough bleed-
ing/spotting by initiating a withdrawal bleeding has 
been shown to reduce the overall number of bleeding 
days, bleeding episodes and menses, and the number 
of days with pain in women suffering from primary 
dysmenorrhoea.
Acknowledgements  Medical writing support was 
provided by Matt Weitz and Clare Wheatcroft 
(of inScience Communications) during the 
preparation of this manuscript. This support was 
funded by Bayer HealthCare Pharmaceuticals. 
The authors would like to thank Dr Daniela 
Rouskova of Bayer HealthCare Pharmaceuticals 
for preparation of the clinical study report.
Funding  This study was funded by Bayer HealthCare 
Pharmaceuticals, Berlin, Germany, the manufacturer 
of ethinylestradiol 20 µg/drospirenone 3 mg.
Competing interests  Thomas Strowitzki has acted as 
a speaker for Bayer HealthCare Pharmaceuticals 
at various symposia and congresses. Bodo 
Kirsch and Jörg Elliesen are employees of 
Bayer HealthCare Pharmaceuticals.
06_jfprhc-2011-100225.indd   100 06_jfprhc-2011-100225.indd   100 3/23/2012   9:58:50 PM 3/23/2012   9:58:50 PMEE/DRSP regimen and dysmenorrhoea
101 J Fam Plann Reprod Health Care April 2012 Vol 38 No 2
Provenance and peer review Not  commissioned; 
externally peer reviewed.
References
 1  Coco AS. Primary dysmenorrhea. Am Fam Physician 
1999;60:489–496.
 2  French L. Dysmenorrhea. Am Fam Physician 2005;71:285–291.
 3  Dawood MY. Primary dysmenorrhea: advances in pathogenesis 
and management. Obstet Gynecol 2006;108:428–441.
 4  Davis AR, Westhoff CL. Primary dysmenorrhea in adolescent 
girls and treatment with oral contraceptives. J Pediatr Adolesc 
Gynecol 2001;14:3–8.
 5  Bjorkman DJ. Current status of nonsteroidal anti-inflammatory 
drug (NSAID) use in the United States: risk factors and 
frequency of complications. Am J Med 1999;107:3S–8S; 
discussion 8S.
 6  Wong CL, Farquhar C, Roberts H, et al. Oral contraceptive 
pill for primary dysmenorrhoea. Cochrane Database Syst Rev 
2009;4:CD002120.
 7  Edelman AB, Gallo MF, Jensen JT, et al. Continuous or 
extended cycle vs cyclic use of combined oral contraceptives for 
contraception. Cochrane Database Syst Rev 2005;3:CD004695.
 8  Andersch B, Milsom I. An epidemiologic study of young women 
with dysmenorrhea. Am J Obstet Gynecol 1982;144:655–660.
 9  Sulak PJ, Cressman BE, Waldrop E, et al. Extending the 
duration of active oral contraceptive pills to manage hormone 
withdrawal symptoms. Obstet Gynecol 1997;89:179–183.
10  Machado RB, de Melo NR, Maia H Jr. Bleeding patterns 
and menstrual-related symptoms with the continuous use of a 
contraceptive combination of ethinylestradiol and drospirenone: 
a randomized study. Contraception 2010;81:215–222.
11  Seidman DS, Yeshaya A, Ber A, et al. A prospective follow-up 
of two 21/7 cycles followed by two extended regimen 84/7 
cycles with contraceptive pills containing ethinyl estradiol and 
drospirenone. Isr Med Assoc J 2010;12:400–405.
12  Kwiecien M, Edelman A, Nichols MD, et al. Bleeding patterns 
and patient acceptability of standard or continuous dosing 
regimens of a low-dose oral contraceptive: a randomized trial. 
Contraception 2003;67:9–13.
13  Göretzlehner G, Waldmann-Rex S, Schramm GA. Extended 
cycles with the combined oral contraceptive chlormadinone 
acetate 2 mg/ethinylestradiol 0.03 mg: pooled analysis of data 
from three large-scale, non-interventional, observational studies. 
Clin Drug Investig 2011;31:269–277.
06_jfprhc-2011-100225.indd   101 06_jfprhc-2011-100225.indd   101 3/23/2012   9:58:50 PM 3/23/2012   9:58:50 PM